

Enier® Tablets

(Betahistine Dihydrochloride)

COMPOSITION:

Enier® 8mg Tablets
Each tablet contains:
Betahistine Dihydrochloride BP8mg

Enier® 16mg Tablets
Each tablet contains:
Betahistine Dihydrochloride BP16mg

Enier® 24mg Tablets
Each tablet contains:
Betahistine Dihydrochloride BP24mg

PHARMACOLOGICAL ACTION:

Betahistine dihydrochloride is an analogue of histamine. It is completely absorbed after oral administration. The mean plasma half-life is 3-4 hours and excretion is virtually complete in the urine within 24 hours in the form of the metabolite 2-pyridylacetic acid.

MODE OF ACTION:

The mechanism of action of betahistine is not known. Pharmacological testing in animals has shown that the blood circulation in the striae vascularis of the inner ear improves, probably by means of a relaxation of the precapillary sphincters of the microcirculation of the inner ear. The mode of action of betahistine was believed to be a direct stimulating (agonistic) effect on H1 receptors located on blood vessels in the inner ear. This would give rise to local vasodilation and increased permeability, which would help reverse the underlying problem of endolymphatic hydrops. In addition, betahistine has an antagonistic effects at H3 receptors, and increases the levels of neurotransmitters released from the nerve endings.

INDICATIONS:

Symptomatic treatment of:
• Vertigo associated with Ménière's Syndrome
• Vestibular vertigo

CONTRA-INDICATIONS:

• Hypersensitivity to any of the ingredients
• Patients with active peptic ulcer
• Patients with phaeochromocytoma

DOSAGE:

Adult dosage
The dosage for adults is 24-48mg in divided doses

Three times daily dosing

8mg tablets: 1-2 tablets three times a day
16mg tablets: ½-1 tablets three times a day

Twice daily dosing

24mg tablets: 1 tablet twice a day

OR

As directed by the physician

SIDE-EFFECTS:

Gastro-intestinal disturbances, headache and skin rashes have been reported

SPECIAL PRECAUTIONS

Caution should be exercised when betahistine dihydrochloride is given to patients with a history of peptic ulcer or asthmatic patients. Concomitant use with antihistamines should be avoided.

PREGNANCY:

There are no well-controlled studies of betahistine use by pregnant women. Therefore, this medication should be used during pregnancy or in women of childbearing potential only if benefits outweigh potential risk.

BREAST-FEEDING:

It is not known whether betahistine passes into breast milk. It should be used during breast-feeding only if the potential benefits outweigh the possible risks.

CHILDREN:

This medication is not recommended for use by children.

OVERDOSAGE AND ITS TREATMENT:

Nausea, vomiting and headache are the more common symptoms. Hypotension could possibly occur. There is no specific antidote. Treatment could include stomach emptying by inducing emesis or by lavage. Further treatment is symptomatic and supportive.

STABILITY:

See expiry on the pack

PRESENTATION:

Enier® 8mg tablets in a pack of 30's
Enier® 16mg tablets in a pack of 30's
Enier® 24mg tablets in a pack of 30's

INSTRUCTIONS:

Keep out of reach of children. Avoid exposure to heat, light and humidity. Store between 15 to 30°C. Improper storage may deteriorate the medicine.

Manufactured by:
SAMI Pharmaceuticals (Pvt.) Ltd.
F-95, S.I.T.E., Karachi-Pakistan
www.samipharmapk.com

P000928/S

اینیئر ٹیبلٹ
(بیتا ہستین ڈائی ہائیڈروکلورائیڈ)

خوراک: ڈاکٹر کی ہدایت کے مطابق استعمال کریں

ہدایات: بیچوں کی پہنچ سے دور رکھیں

دوا کو دھوپ، گرمی اور نمی سے محفوظ رکھیں۔ اسے ۱۵ سے ۳۰ ڈگری سینٹی گریڈ

کے درمیان میں رکھیں ورنہ دوا خراب ہو جائیگی

R.N-0414A/03/16/Pampac

120 mm

210 mm